ArticleCancer cell2014
Inhibit globally, act locally: CDK7 inhibitors in cancer therapy.
Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- CDK7 inhibition promotes glioblastoma cell death through convergent transcriptional and metabolic stress pathways.Clinical and translational medicine · 2025Article
- Article
- Transcriptional Stress Induces the Generation of DoGs in Cancer Cells.Non-coding RNA · 2024Article
- Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.Pharmacological reports : PR · 2022Article
- Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations.Biomedicines · 2021Article
- CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma.EMBO reports · 2021Article
- The Application Progress of Patient-Derived Tumor Xenograft Models After Cholangiocarcinoma Surgeries.Frontiers in oncology · 2021Review
- Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.Therapeutic advances in musculoskeletal disease · 2021Article
- Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.International journal of biological sciences · 2020Article
- Article
- Article
- Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.Transcription · 2019Review
- CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.OncoTargets and therapy · 2019Article
- Anti-tumor Drug THZ1 Suppresses TGFβ2-mediated EMT in Lens Epithelial Cells via Notch and TGFβ/Smad Signaling Pathway.Journal of Cancer · 2019Article
- Article
- Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation.Journal of Cancer · 2018Article
- Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.Cell reports · 2017Article
- Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.Molecular pharmacology · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclin-dependent kinases (CDKs) are involved in temporal control of the cell cycle and transcription and play central roles in cancer development and metastasis. Recently, Kwiatkowski and colleagues identified a novel CDK7-specific inhibitor, THZ1, that hinders proliferation in cancer cell lines and dampens global transcription in T cell leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.